| Bioactivity | Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent[1]. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability[1]. |
| In Vivo | Vutiglabridin (HSG4112) fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner. Vutiglabridin (orally administered with 10, 30, or 100 mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice[2]. Animal Model: |
| Name | Vutiglabridin |
| CAS | 1800188-47-9 |
| Formula | C22H26O4 |
| Molar Mass | 354.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. In Yong Bae, et al. Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent. Pharmaceutics. 2020 Feb 3;12(2):127. [2]. Leo Sungwong Choi, et al. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. Int J Obes (Lond). 2021 Jan;45(1):130-142. |
Vutiglabridin
CAS: 1800188-47-9 F: C22H26O4 W: 354.44
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent. Vutiglabridin, an optimized structural anal
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.